Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL247 Target Snapshot

Human immunodeficiency virus type 1 reverse transcriptase · SINGLE PROTEIN · Human immunodeficiency virus 1

Back to Search Search this target Browse approvals Evidence Card
8,652Compounds
2,087Assays
35Approved Drugs
13,352.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Human immunodeficiency virus type 1 reverse transcriptase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 31 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q72547. Start with HIV infection, then reuse UniProt Q72547 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with HIV infection, then reuse UniProt Q72547 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 31 linked drugs
Open source guide
Disease program
HIV infection

Human immunodeficiency virus type 1 reverse transcriptase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 31 linked drugs remain visible in the same block.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include ABACAVIR SULFATE, AMDOXOVIR, APRICITABINE, ATEVIRDINE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 31 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus type 1 reverse transcriptase as ChEMBL target CHEMBL247, mapped to UniProt Q72547. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human immunodeficiency virus type 1 reverse transcriptase
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-14
ChEMBL target ID
CHEMBL247
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q72547
Reverse transcriptase/RNaseH
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Human immunodeficiency virus type 1 reverse transcriptase is the right protein anchor across sources, using UniProt Q72547 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 31 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHuman immunodeficiency virus type 1 reverse transcriptase
Target TypeSINGLE PROTEIN
OrganismHuman immunodeficiency virus 1
UniProtQ72547
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReverse transcriptase/RNaseH
UniProt AccessionQ72547
Component TypeProtein
Sequence Length566 aa

Reverse transcriptase/RNaseH

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Human immunodeficiency virus type 1 reverse transcriptase, mapped to UniProt Q72547. ChEMBL maps the protein component as Reverse transcriptase/RNaseH. Sequence length is 566 aa.

Mapped IDQ72547
Review nameHuman immunodeficiency virus type 1 reverse transcriptase
OrganismHuman immunodeficiency virus 1
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Human immunodeficiency virus type 1 reverse transcriptase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
HIV infection
31 linked drugs · 31 direct · 31 efficacy
Linked drugABACAVIR SULFATE
Linked drugAMDOXOVIR
Linked drugAPRICITABINE
Linked drugATEVIRDINE MESYLATE
Approved-linked Approved
HIV-1 infection
19 linked drugs · 19 direct · 19 efficacy
Linked drugCENSAVUDINE
Linked drugDAPIVIRINE
Linked drugDORAVIRINE
Linked drugEFAVIRENZ
Approved-linked Approved
viral disease
12 linked drugs · 12 direct · 12 efficacy
Linked drugDIDANOSINE
Linked drugDORAVIRINE
Linked drugEFAVIRENZ
Linked drugEMTRICITABINE
Approved-linked Approved
infection
9 linked drugs · 9 direct · 9 efficacy
Linked drugDAPIVIRINE
Linked drugEFAVIRENZ
Linked drugEMTRICITABINE
Linked drugETRAVIRINE
Approved-linked Approved
chronic hepatitis B virus infection
7 linked drugs · 7 direct · 7 efficacy
Linked drugELVUCITABINE
Linked drugEMTRICITABINE
Linked drugLAMIVUDINE
Linked drugTENOFOVIR ALAFENAMIDE
Approved-linked Approved
hepatitis B virus infection
6 linked drugs · 6 direct · 6 efficacy
Linked drugEMTRICITABINE
Linked drugLAMIVUDINE
Linked drugTENOFOVIR ALAFENAMIDE
Linked drugTENOFOVIR ALAFENAMIDE FUMARATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include ABACAVIR SULFATE, AMDOXOVIR, APRICITABINE, ATEVIRDINE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHIV infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

35
Approved
5
Phase III
22
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC5010,772.0
KI817.0
EC501,607.0
KD156.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3621607 10.8 IC50 0.016 Preclinical
CHEMBL3621611 10.74 IC50 0.018 Preclinical
CHEMBL3621604 10.72 IC50 0.019 Preclinical
CHEMBL3621613 10.72 IC50 0.019 Preclinical
CHEMBL3621605 10.57 IC50 0.027 Preclinical
CHEMBL3621609 10.57 IC50 0.027 Preclinical
CHEMBL3621614 10.55 IC50 0.028 Preclinical
CHEMBL513181 10.52 EC50 0.03 Preclinical
CHEMBL5398494 10.52 EC50 0.03 Preclinical
CHEMBL3621606 10.46 IC50 0.035 Preclinical
Distribution

pChEMBL Value Distribution

1311
5.0
1305
5.5
1484
6.0
1571
6.5
1394
7.0
1020
7.5
676
8.0
239
8.5
107
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

DORAVIRINE
CHEMBL2364608
Approved 2018
Properties Compare Identifier
RILPIVIRINE
CHEMBL175691
Approved 2011
Properties Compare Identifier
ETRAVIRINE
CHEMBL308954
Approved 2008
Properties Compare Identifier
ATAZANAVIR
CHEMBL1163
Approved 2003
Properties Compare Identifier
ABACAVIR
CHEMBL1380
Approved 1998
Properties Compare Identifier
EFAVIRENZ
CHEMBL223228
Approved 1998
Properties Compare Identifier
DELAVIRDINE
CHEMBL593
Approved 1997
Properties Compare Identifier
DELAVIRDINE MESYLATE
CHEMBL929
Approved 1997
Properties Compare Identifier
NEVIRAPINE
CHEMBL57
Approved 1996
Properties Compare Identifier
LAMIVUDINE
CHEMBL141
Approved 1995
Properties Compare Identifier
STAVUDINE
CHEMBL991
Approved 1994
Properties Compare Identifier
ZALCITABINE
CHEMBL853
Approved 1992
Properties Compare Identifier
FOSCARNET
CHEMBL666
Approved 1991
Properties Compare Identifier
ZIDOVUDINE
CHEMBL129
Approved 1987
Properties Compare Identifier
CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
Assay Landscape

Assay Landscape

2,087
Total Assays
6,111
Tested Compounds
3
Assay Types
Binding — 1,960 assays, 6,111 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1,341 4,562 6.3
assay format 489 1,187 6.3
cell-based format 130 362 7.1
Functional — 125 assays, 232 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 93 71 6.1
cell-based format 31 161 6.1
cell-free format 1 0 —
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine